| Similar Articles |
|---|
 |
The Motley Fool
March 21, 2005
Rich Duprey |
Inamed Buoyant on Medicis Buyout Breast-implant maker Inamed will be acquired in a $2.8 billion deal with skin-care pharmaceutical Medicis. Inamed investors should now decide whether they want to be a part of Medicis or enjoy the profits realized from the offer.   |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags. |
The Motley Fool
January 15, 2009
Robert Steyer |
Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy. |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note. |
The Motley Fool
August 31, 2007
Rich Smith |
A Healthy Buyback for Medicis? Investors, can Medicis pay its own way? And even if it can, should it? |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
The Motley Fool
September 25, 2008
Brian Orelli |
Medicis Restates, Investors Panic Medicis says it'll have to restate earnings. |
The Motley Fool
February 28, 2011
Cindy Johnson |
Medicis Pharmaceutical Shares Popped: What You Need to Know Medicis Pharmaceutical Corporation popped 26% in intraday trading today after reporting an inline quarter and announcing a licensing agreement with Teva Pharmaceutical Industries. |
The Motley Fool
February 9, 2004
Bill Mann |
Sickly Sweet Stock Split Rocky Mountain Chocolate Factory splits a $13 stock "to increase shareholder value." But in this case, splitting the stock does nothing of the sort. |
The Motley Fool
March 19, 2009
Brian Orelli |
Teva: An Equal-Opportunity Bully Making money by picking on the little guy, too. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note. |
The Motley Fool
July 28, 2011 |
Medicis Pharmaceutical Earnings Preview Medicis Pharmaceutical will unveil its latest earnings on Tuesday, August 2. |
The Motley Fool
May 19, 2006
Jim Mueller |
Foolish Forecast: Mentor's Uncertain Results Factors outside of the cosmetic surgery products maker's control are leading to short-term uncertainty. Investors, take note. |
Chemistry World
September 6, 2012
Andrew Turley |
Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products. |
The Motley Fool
May 27, 2009
Brian Orelli |
A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news. |
The Motley Fool
September 22, 2010
Seth Jayson |
Will Medicis Pharmaceutical Whiff on Revenues Next Quarter? Medicis Pharmaceutical's year-over-year revenue grew 23.2%, and its AR grew 40.5%. That's a yellow flag. |
The Motley Fool
December 20, 2010
Seth Jayson |
Should You Get Out of Medicis Pharmaceutical Before Next Quarter? The numbers don't paint a clear picture. For the last fully reported fiscal quarter, Medicis Pharmaceutical's year-over-year revenue grew 16.8%, and its AR grew 138.1%. That's a yellow flag. |
BusinessWeek
October 13, 2003
Arlene Weintraub |
He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug? |
The Motley Fool
January 31, 2007
Brian Lawler |
No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now. |
The Motley Fool
September 12, 2008
Brian Lawler |
A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches. |
The Motley Fool
July 28, 2011
Seth Jayson |
Why Medicis Pharmaceutical May Be About to Take Off Is the current inventory situation at Medicis Pharmaceutical out of line? |
The Motley Fool
February 9, 2006
Stephen D. Simpson |
Mentor Needs Some Prettying Up Until new products are approved or acquired, the aesthetics and urology company seems stuck in suspended animation. Just standing in place is not going to build much shareholder value. |
The Motley Fool
April 14, 2005
Rich Duprey |
Mentor the Winner on Implants An FDA panel gives Mentor the right to market breast implants after denying Inamed's application. On the news, Inamed's stock fell by more than 3%, and then nearly 7% in early morning trading. |
The Motley Fool
March 15, 2010
Rick Aristotle Munarriz |
4 Dividend Stocks Showing You the Money Staples... Medicis... Applied Materials... Lennox International... |
The Motley Fool
November 17, 2008
Brian Orelli |
Beauty Can Be a Beast Pinched pocketbooks are likely to hurt cosmetic-pharmaceutical companies more than any FDA warning. |
